North East based CPI announces project with GSK and AstraZeneca to accelerate optimisation of oral solid drug formulations

CPI and the University of Strathclyde, in strategic partnership with GSK and AstraZeneca, have announced that work has begun on Grand Challenge 1, a project to develop an innovative continuous direct compression (CDC) platform at the new Medicines Manufacturing Innovation Centre.  The platform will enable oral solid dosage medicines to be formulated more robustly and efficiently.

CDC is a continuous manufacturing process that allows much greater process control than traditional batch-type pharmaceutical manufacturing methods, enabling rapid production of formulations at a range of scales. In addition, CDC offers shorter optimisation times than batch-type processes and therefore more efficient use of starting materials. The aim of Grand Challenge 1 is to further build on this process efficiency by developing a digitally-twinned CDC platform and workflow, allowing scientists to understand and optimise their formulation process in digital space. This will reduce the amount of starting materials needed for optimisation and reduce the overall cost of the technology for the end-user.

The first stage of the project is to create a flexible plug-and-play development platform. This will involve adapting and improving existing CDC models, which are often inflexible and specific for individual equipment manufacturers. Novel process analytical technology (PAT) will also be integrated into this platform.

Professor Alastair Florence, University of Strathclyde said: “The key innovation of a digital twin for the direct compression platform will radically cut down the amount of material needed to optimise formulations. It will allow companies to model their processes in digital space, providing a much deeper understanding of how APIs and excipients will perform, leading to a reduction in development times.”

The project is receiving funding from UKRI, Scottish Enterprise and the consortium’s industry partners, and is split into two phases. The development phase of the project is already underway at CMAC – the future manufacturing research hub within the University of Strathclyde.  The aim is to have a development platform operational by Q3 2020. Following this initial phase, project work will be transferred to the MMIC in Glasgow upon the centre’s completion in 2021.

Funded by UK Research and Innovation and Scottish Enterprise, the MMIC aims to ensure that the UK is a technological and innovation leader in pharmaceutical and fine chemical manufacturing, addressing some of the key challenges facing the industry. The facility will focus on the development of improved manufacturing processes, enabling a more agile, responsive medicines supply chain. The GMP-capable environment will enable new and disruptive technologies to be proven at scale, allowing the rapid adoption of next-generation processes that reduce risk, cut costs and save time.

Dave Tudor, Managing Director of the Medicines Manufacturing Innovation Centre at CPI said: “The strength of the open collaboration between CPI, GSK, AstraZeneca and University of Strathclyde cannot be overstated; we are happy to be providing our strategic and technical support. The flexible platform developed at the centre through Grand Challenge 1 will be a national asset, helping pharmaceutical companies to develop formulations faster and at reduced cost.”

North East based CPI announces project with GSK and AstraZeneca to accelerate optimisation of oral solid drug formulations

Other News

Follow NETPark On Social Media

Keep up to date with the latest NETPark news and events.

NETPark Logo

The North East Technology Park provides a dynamic and supportive environment to accelerate the growth of ambitious, innovative, high tech companies into global markets. NETPark encourages collaborative multidisciplinary links, driving innovation, enterprise and economic prosperity.
We provide companies with access to a focused and international community where talent flourishes, ideas are generated and businesses have the support and resources to compete with the best in the world.

NETPark North East Technology Park

NETPark, North East Technology Park,
Sedgefield, County Durham TS21 3FD

Call Us: (+44) 01740 625250

It fits perfectly for us that we’re surrounded by like-minded companies at NETPark. There are a number of highly skilled people in the area who can help us grow our business. The facilities and services offered by NETPark are first class, they make office life simple and engaging.

Stuart Wilson, - CEO, Ascarii

CPI has developed a specialist offering to support SMEs looking to develop their printable electronics applications and our partnership with Business Durham has been instrumental in attracting several SMEs to locate here in the region.

Dr Jon Helliwell, - Director of Printable Electronics, CPI

Access to quality facilities was one of the main drivers for deciding to locate the business at the NETPark. We have been able to use this as a launch pad to link into support from CPI and world-class expertise from Durham University.

Steve Clements, - Managing Director, aXenic

The proximity to the universities and the infrastructure are very important factors. Ultimately having a presence in Europe is very valuable to us and we intend to stay at NETPark for many years to come.

Dr Arnab Basu, - CEO, Kromek

We initially came because of the printable electronics centre but access to a highly skilled semi conductor workforce in the North East has been a key factor in us staying and growing here, as well as the value for money office space and the access to funding.

Ken Williamson, - COO, PragmatIC Printing

The quality of the facilities at NETPark and the attitude of staff is first class. It has a really dynamic, innovative atmosphere.

Dr Neil Loxley, - Chief executive, IBEX
Go to Top